Special Issue

Topic: Genomic and Genetic Alterations Associated with Cancer Drug Resistance

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 20 Nov 2024

Guest Editor(s)

Dr. Christophe P. Nicot
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas, KS, USA.

Special Issue Introduction

Despite the advancements in cancer therapies over the past decade, which have improved cancer patients' life expectancy, drug resistance remains a significant challenge in cancer treatment. Cancer cells frequently acquire resistance to therapies and evade the immune system through various mechanisms, leading to treatment failure and poor prognosis. Commonly reported tumor resistance mechanisms are genetic mutations (such as BRCA1 in breast cancer or EGFR in lung cancer) and epigenetic alterations (such as non-coding RNAs), abnormally enhanced drug efflux (such as P-glycoprotein) and alteration in drug metabolism (i.e., cytochrome P450 enzymes), and deregulation of DNA repair mechanisms and defective apoptotic signaling pathways. Moreover, alteration of the tumor microenvironment (TME) and dormancy of cancer stem cells are associated with residual disease and tumor repopulation after treatment. These mechanisms have been reported to act independently or in combination to promote drug resistance. The complexity of drug resistance highlights the importance of developing combination therapies and personalized treatments to overcome or prevent the emergence of resistant tumor clones in cancer patients. This Special Issue aims to publish original research articles, clinical reports, and review articles that shed light on drug resistance in cancer treatment. 

Proposed topics include, but are not limited to: 

1. Genetic mutations or gene expression associated with drug sensitivity and drug resistance;

2. Epigenetic modifications in drug-resistant cancer cells; 

3. Non-coding RNAs associated with cancer drug resistance;

4. Biomarkers for the prediction of drug response or failure;

5. Tumor microenvironment (TME) and drug resistance;

6. Immunotherapy and cancer vaccines to eliminate drug-resistant cancer cells;

7. Novel therapies to overcome the resistance of cancer cells.

Submission Deadline

20 Nov 2024

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR240408
Submission Deadline: 20 Nov 2024
Contacts: Lori, Assistant Editor, Lori@cdrjournal.com

Published Articles

Coming soon
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/